Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Morseus01
Morseus01 Oct. 25 at 8:43 PM
$AFMD are we trending again? Sign we’re going back up finally?
0 · Reply
deathknight
deathknight Oct. 25 at 7:43 PM
$AFMD for those still whining about the management, this "incompetent" management secured total 7+ billion collaboration deals, created multiple promising clinical pipelines and successfully derisked their products and platform without huge dilution. They can EASILY avoid filing insolvency by selling 20m shares at $1 dollar or less and have their payroll running for another year or two -- most biotechs would certain do that. I do hope they can be a bit more transparent and communicate better. But I give them credit where it's due.
1 · Reply
DrPump_
DrPump_ Oct. 25 at 3:16 PM
$AFMD AFM24 … A DCR of 77%, along with some long, sustained responses. https://www.sciencedirect.com/science/article/abs/pii/S1556086425016843
1 · Reply
deathknight
deathknight Oct. 25 at 1:44 PM
$AFMD while digging info for the "second creditor meeting", I happen to found something much more interesting-- on the Aug 1st announcement, we have the creditors' committee member announced. Among the three member panel there is Ms. Susanne Spieler -- guess for whom she represents (aka her employer)? It's none other than Affimed N.V. Ms.Spieler was a SVP of Affimed N.V. for general counsel and compliance. More interestingly, she just left the company this month and joint another company -- hard to imagine they would not pick her replacement if another creditors' meeting is coming and actually, if the creditors' committee is still needed. Such replacement would need to be publicly announced quickly and likely before she left the post.
3 · Reply
Hodl707
Hodl707 Oct. 25 at 3:29 AM
$AFMD closed at 900% after hours 900%
1 · Reply
Hodl707
Hodl707 Oct. 24 at 7:44 PM
$AFMD does anybody know anything about November 5? Is there anything on November 5 that we should know about
2 · Reply
Think_Bigly
Think_Bigly Oct. 24 at 3:01 PM
$AFMD .005 for 90 minutes. Are we gonna get a bid?
1 · Reply
Think_Bigly
Think_Bigly Oct. 23 at 10:42 PM
$AFMD It means they're going to need a CSO to audit trials..
1 · Reply
DrPump_
DrPump_ Oct. 23 at 8:09 PM
$AFMD some two interesting papers featuring Affimed tech this week. One wrote by Affimed: https://pmc.ncbi.nlm.nih.gov/articles/PMC12537995/ One wrote by MDA https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00405-2
2 · Reply
Hodl707
Hodl707 Oct. 22 at 10:23 PM
$AFMD lol
1 · Reply
Latest News on AFMD
No data available.
Morseus01
Morseus01 Oct. 25 at 8:43 PM
$AFMD are we trending again? Sign we’re going back up finally?
0 · Reply
deathknight
deathknight Oct. 25 at 7:43 PM
$AFMD for those still whining about the management, this "incompetent" management secured total 7+ billion collaboration deals, created multiple promising clinical pipelines and successfully derisked their products and platform without huge dilution. They can EASILY avoid filing insolvency by selling 20m shares at $1 dollar or less and have their payroll running for another year or two -- most biotechs would certain do that. I do hope they can be a bit more transparent and communicate better. But I give them credit where it's due.
1 · Reply
DrPump_
DrPump_ Oct. 25 at 3:16 PM
$AFMD AFM24 … A DCR of 77%, along with some long, sustained responses. https://www.sciencedirect.com/science/article/abs/pii/S1556086425016843
1 · Reply
deathknight
deathknight Oct. 25 at 1:44 PM
$AFMD while digging info for the "second creditor meeting", I happen to found something much more interesting-- on the Aug 1st announcement, we have the creditors' committee member announced. Among the three member panel there is Ms. Susanne Spieler -- guess for whom she represents (aka her employer)? It's none other than Affimed N.V. Ms.Spieler was a SVP of Affimed N.V. for general counsel and compliance. More interestingly, she just left the company this month and joint another company -- hard to imagine they would not pick her replacement if another creditors' meeting is coming and actually, if the creditors' committee is still needed. Such replacement would need to be publicly announced quickly and likely before she left the post.
3 · Reply
Hodl707
Hodl707 Oct. 25 at 3:29 AM
$AFMD closed at 900% after hours 900%
1 · Reply
Hodl707
Hodl707 Oct. 24 at 7:44 PM
$AFMD does anybody know anything about November 5? Is there anything on November 5 that we should know about
2 · Reply
Think_Bigly
Think_Bigly Oct. 24 at 3:01 PM
$AFMD .005 for 90 minutes. Are we gonna get a bid?
1 · Reply
Think_Bigly
Think_Bigly Oct. 23 at 10:42 PM
$AFMD It means they're going to need a CSO to audit trials..
1 · Reply
DrPump_
DrPump_ Oct. 23 at 8:09 PM
$AFMD some two interesting papers featuring Affimed tech this week. One wrote by Affimed: https://pmc.ncbi.nlm.nih.gov/articles/PMC12537995/ One wrote by MDA https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00405-2
2 · Reply
Hodl707
Hodl707 Oct. 22 at 10:23 PM
$AFMD lol
1 · Reply
Hodl707
Hodl707 Oct. 22 at 3:53 AM
$AFMD Melvin Little, is he here to aid in the asset, transfer the hand off
2 · Reply
Hodl707
Hodl707 Oct. 22 at 3:26 AM
$AFMD what could this mean I don’t think it’s a duplicate
1 · Reply
deathknight
deathknight Oct. 21 at 11:33 AM
$AFMD anyone has idea who this folk is? He has been listed as CSO since August but I have no access to his profile and have no idea he's legit.
1 · Reply
Hodl707
Hodl707 Oct. 19 at 6:49 PM
$AFMD one of the cleanest recap shells biotech has ever seen
0 · Reply
Hodl707
Hodl707 Oct. 18 at 11:56 PM
$AFMD • The syndicate controls the float • The cap table is sterilized • The optics are frozen • The backend equity is being structured under NDA
0 · Reply
Hodl707
Hodl707 Oct. 18 at 10:00 PM
$AFMD has anybody really asked themselves why there isn’t any trading going on anymore my volume dropped what’s the answer? Is it that they flushed out all the retail as well? Someone tell me what else could it be?
1 · Reply
deathknight
deathknight Oct. 18 at 11:35 AM
$ARTV received fast track designation yesterday and it's stock more than doubled in a single day. $AFMD received fast track for AFM24 last May and RMAT for AFM13 last December, our price dropped >5% on each time. Also almost every time we publish promising data, share price dropped... make that make sense...
3 · Reply
Hodl707
Hodl707 Oct. 18 at 9:09 AM
$AFMD with the by volume 5/16 through 5/19 the price should have rocket. It’s double digits dollars that’s what makes it engineered that they kept the price down between .18 and $.22. They strategically accumulated a huge amount.
0 · Reply
Think_Bigly
Think_Bigly Oct. 18 at 4:51 AM
$AFMD Published: 21 August 2025 - AFTER the filing - "The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS" https://www.nature.com/articles/s41467-025-63069-y#Fun
0 · Reply
Think_Bigly
Think_Bigly Oct. 18 at 4:45 AM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Oct. 18 at 4:35 AM
Taking some time. 13 weeks is common. However, $AFMD may have 2-3 bids. Must be interest in the 3rd largest licensing deal ever done.. and they didn't even have all their pristine trial data at the time. - The Genentech-Affimed partnership is outvalued by only two larger collaborations, both of which involve Merck. The pharma giant on March 8 launched an up-to-$5.77 billion collaboration with Eisai
0 · Reply
Think_Bigly
Think_Bigly Oct. 17 at 2:20 AM
$AFMD per Gilde - Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing the company with one of the most mature pipelines in the innate immune oncology field. The company’s lead product candidate has demonstrated transformational data in patients suffering from end-stage Hodgkin’s lymphoma. If these results can be replicated, Affimed has the potential to lead a paradigm shift in oncology by offering a life-changing new treatment option for thousands of patients. In addition, - Affimed’s second product candidate has shown very promising data in end-stage lung cancer patients, a group that is rapidly growing and for which treatment options are virtually non-existent. Affimed’s pipeline is based on its proprietary ROCK® platform, which enables the destruction of tumors in a targeted manner. - Affimed’s 3rd product, innate cell engager AFM28, eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nothing else close.
0 · Reply